Article
Pharmacology & Pharmacy
Natsumi Mizuno, Yoshiki Yanagawa
Summary: In this study, it was found that tofacitinib enhanced IFN-gamma-induced MHC II expression in macrophages by transcriptional regulation through induction of CIITA, while decreasing the expression of CD86.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Oncology
Evelien J. M. de Jong, Quisette P. Janssen, Tessa F. A. Simons, Marc G. Besselink, Bert A. Bonsing, Stefan A. W. Bouwense, Sandra M. E. Geurts, Marjolein Y. Homs, Vincent E. de Meijer, Vivianne C. G. Tjan-Heijnen, Hanneke W. M. van Laarhoven, Liselot B. J. Valkenburg-van Iersel, Johanna W. Wilmink, Lydia G. van der Geest, Bas Groot Koerkamp, Judith de Vos-Geelen
Summary: In a nationwide cohort of patients with pancreatic ductal adenocarcinoma, adjuvant GEMCAP was associated with superior survival compared to GEM monotherapy.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Multidisciplinary Sciences
Daniel R. Principe, Alexandre F. Aissa, Sandeep Kumar, Thao N. D. Pham, Patrick W. Underwood, Rakesh Nair, Rong Ke, Basabi Rana, Jose G. Trevino, Hidayatullah G. Munshi, Elizaveta Benevolenskaya, Ajay Rana
Summary: There is currently no effective treatment for pancreatic ductal adenocarcinoma (PDAC). In this study, researchers identified a subset of gemcitabine-resistant tumor cells enriched for calcium/calmodulin signaling. Inhibition of calcium-dependent calmodulin activation led to the loss of drug-resistant phenotypes, and calcium chelation or depletion impaired ERK activation and restored therapeutic responses to gemcitabine. Calcium channel blockers also enhanced therapeutic responses to gemcitabine.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Article
Oncology
Louise Skau Rasmussen, Stine B. Winther, Inna M. Chen, Britta Weber, Lise Ventzel, Gabor Liposits, Julia Sidenius Johansen, Soenke Detlefsen, Ida Egendal, Susy Shim, Signe Christensen, Per Pfeiffer, Morten Ladekarl
Summary: This study aims to investigate whether reduced dose GemNab is superior to full dose Gem in patients with resectable pancreatic cancer. The study will explore various endpoints including progression-free survival, overall survival, overall response rate, quality of life, toxicity, and rate of hospitalizations. The correlation between blood inflammatory markers, circulating tumor DNA, tissue biomarkers, and chemotherapy resistance will also be studied, along with measures of frailty to assess personalized treatment allocation or interventions.
Article
Medicine, Research & Experimental
Yanshen Chen, Hua Liu, Qiaowei Zheng, Houli Li, Huining You, Yan Feng, Weiyi Feng
Summary: This study observes the previously neglected phenomenon that continuous low-dose administration of certain antineoplastic agents can promote tumorigenesis and tumor progression. The study investigates the underlying mechanisms and finds that these agents can stimulate tumor cell functions directly and enhance tumor angiogenesis indirectly. These findings raise awareness of potential risks in current continuous low-dose chemotherapy regimens.
Article
Nutrition & Dietetics
Susie Youn, Angela Chen, Vincent Ha, Carole Chambers, Dean T. Eurich, Michael McCall, Michael B. Sawyer
Summary: The study found that adjusting nab-paclitaxel doses based on muscle mass can predict the risk of chemotherapy toxicity. Factors like BMI, body surface area, and initial drug doses did not significantly impact toxicity occurrence.
CLINICAL NUTRITION
(2021)
Letter
Oncology
Shuling Chen, Jiaxin Li, Aoran Dong, Zelong Liu, Meiyan Zhu, Meng Jin, Guangyan Wei, Shuang Wu, Yan Wang, Yong Chen, Zhenwei Peng
Summary: This study compared the efficacy and safety of combination therapy with immunotherapy and radiotherapy versus chemotherapy alone for patients with locally advanced pancreatic adenocarcinoma (LAPC). The combination treatment group showed significant advantages in median overall survival and progression-free survival compared to the chemotherapy alone group. However, the incidence of severe adverse events did not differ significantly between the two groups. Therefore, combination therapy appears to be an effective and safe treatment option for LAPC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Article
Oncology
Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni
Summary: In this randomized, open-label trial, adjuvant nab-paclitaxel + gemcitabine was compared with gemcitabine alone for resected pancreatic ductal adenocarcinoma. The study found that although nab-paclitaxel + gemcitabine showed favorable overall survival, it did not meet the primary endpoint of independently assessed disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Jessica L. Chitty, Michelle Yam, Lara Perryman, Amelia L. Parker, Joanna N. Skhinas, Yordanos F. I. Setargew, Ellie T. Y. Mok, Emmi Tran, Rhiannon D. Grant, Sharissa L. Latham, Brooke A. Pereira, Shona C. Ritchie, Kendelle J. Murphy, Michael Trpceski, Alison D. Findlay, Pauline Melenec, Elysse C. Filipe, Audrey Nadalini, Sipiththa Velayuthar, Gretel Major, Kaitlin Wyllie, Michael Papanicolaou, Shivanjali Ratnaseelan, Phoebe A. Phillips, George Sharbeen, Janet Youkhana, Alice Russo, Antonia Blackwell, Jordan F. Hastings, Morghan C. Lucas, Cecilia R. Chambers, Daniel A. Reed, Janett Stoehr, Claire Vennin, Ruth Pidsley, Anaiis Zaratzian, Andrew M. Da Silva, Michael Tayao, Brett Charlton, David Herrmann, Max Nobis, Susan J. Clark, Andrew V. Biankin, Amber L. Johns, David R. Croucher, Adnan Nagrial, Anthony J. Gill, Sean M. Grimmond, Amber L. Johns, Anthony J. Gill, Lorraine A. Chantrill, Paul Timpson, Angela Chou, Marina Pajic, Tanya Dwarte, David Herrmann, Claire Vennin, Thomas R. Cox, Brooke A. Pereira, Shona C. Ritchie, Daniel A. Reed, Cecilia R. Chambers, Xanthe L. Metcalf, Max Nobis, Gloria Jeong, Lara Kenyon, Nicola Waddell, John V. Pearson, Ann-Marie Patch, Katia Nones, Felicity Newell, Pamela Mukhopadhyay, Venkateswar Addala, Stephen Kazakoff, Oliver Holmes, Conrad Leonard, Scott Wood, Sean M. Grimmond, Oliver Hofmann, Jaswinder S. Samra, Nick Pavlakis, Jennifer Arena, Hilda A. High, Ray Asghari, Neil D. Merrett, Amitabha Das, Peter H. Cosman, Kasim Ismail, Alina Stoita, David Williams, Allan Spigellman, Duncan Mcleo, Judy Kirk, James G. Kench, Peter Grimison, Charbel Sandroussi, Annabel Goodwin, R. Scott Mead, Katherine Tucker, Lesley Andrews, Michael Texler, Cindy Forrest, Mo Ballal, David Fletcher, Maria Beilin, Kynan Feeney, Krishna Epari, Sanjay Mukhedkar, Nikolajs Zeps, Nan Q. Nguyen, Andrew R. Ruszkiewicz, Chris Worthley, John Chen, Mark E. Brooke-Smith, Virginia Papangelis, Andrew D. Clouston, Andrew P. Barbour, Thomas J. O'Rourke, Jonathan W. Fawcett, Kellee Slater, Michael Hatzifotis, Peter Hodgkinson, Mehrdad Nikfarjam, James R. Eshleman, Ralph H. Hruban, Christopher L. Wolfgang, Aldo Scarpa, Rita T. Lawlor, Vincenzo Corbo, Claudio Bassi, Andrew V. Biankin, Nigel B. Jamieson, David K. Chang, Stephan B. Dreyer, Paul Timpson, Thomas R. Cox, Marina Pajic, Anthony J. Gill, Jaswinder S. Samra, Brooke A. Pereira, David Herrmann, Amber L. Johns, Gloria Jeong, Shona C. Ritchie, Daniel A. Reed, Cecilia R. Chambers, Janett Stoehr, Morghan C. Lucas, Joanna N. Skhinas, Lea Abdulkhalek, Max Nobis, Tatjana Schmitz, Victoria Lee, Xanthe L. Metcalf, Sean M. Grimmond, Kym Pham Stewart, Mehreen Arshi, Angela M. Steinmann, Lara Kenyon, Marina Pajic, Paul Timpson, Wolfgang Jarolimek, Thomas R. Cox
Summary: The pan-lysyl oxidase inhibitor PXS-5505 reduces chemotherapy-induced desmoplasia and stiffness, improving chemotherapy response and survival in pancreatic cancer models.
Article
Oncology
Jessica L. Chitty, Michelle Yam, Lara Perryman, Amelia L. Parker, Joanna N. Skhinas, Yordanos F. I. Setargew, Ellie T. Y. Mok, Emmi Tran, Rhiannon D. Grant, Sharissa L. Latham, Brooke A. Pereira, Shona C. Ritchie, Kendelle J. Murphy, Michael Trpceski, Alison D. Findlay, Pauline Melenec, Elysse C. Filipe, Audrey Nadalini, Sipiththa Velayuthar, Gretel Major, Kaitlin Wyllie, Michael Papanicolaou, Shivanjali Ratnaseelan, Phoebe A. Phillips, George Sharbeen, Janet Youkhana, Alice Russo, Antonia Blackwell, Jordan F. Hastings, Morghan C. Lucas, Cecilia R. Chambers, Daniel A. Reed, Janett Stoehr, Claire Vennin, Ruth Pidsley, Anaiis Zaratzian, Andrew M. Da Silva, Michael Tayao, Brett Charlton, David Herrmann, Max Nobis, Susan J. Clark, Andrew V. Biankin, Amber L. Johns, David R. Croucher, Adnan Nagrial, Anthony J. Gill, Sean M. Grimmond, Marina Pajic, Paul Timpson, Wolfgang Jarolimek, Thomas R. Cox
Summary: By inhibiting the activity of pan-lysyl oxidase, PXS-5505 can reduce fibrosis and stiffness in pancreatic tumors, decrease cancer cell invasion and metastasis, and enhance the efficacy of chemotherapy.
Article
Pediatrics
Ramesh Radhika, Milind S. Tullu, Sunil Karande, Umair Ahmed Bargir
Summary: Major Histocompatibility Complex (MHC) Class II deficiency is a rare autosomal recessive primary immunodeficiency caused by mutations in regulatory genes of MHC Class II proteins. This case report describes a 9-month-old girl presenting with repeated pneumonia, lymphocytopenia, and absence of HLA-DR expression on B cells, which led to the diagnosis of MHC Class II deficiency. Genetic analysis identified a homozygous mutation in the RFX-5 gene. Despite the patient's unfortunate outcome, the importance of prenatal diagnosis was emphasized to the parents.
INDIAN JOURNAL OF PEDIATRICS
(2023)
Article
Oncology
Congjun Zhang, Shuangyan Ou, Yuan Zhou, Pei Liu, Peiying Zhang, Ziqian Li, Ruocai Xu, Yuqiang Li
Summary: The study revealed that METTL14 plays a crucial role in gemcitabine resistance in pancreatic cancer, and inhibition of METTL14 can increase the sensitivity of resistant cells to gemcitabine. Transcription factor p65 targets and upregulates METTL14 expression, leading to increased expression of cytidine deaminase (CDA) which inactivates gemcitabine. Depletion of METTL14 restores the response of resistant cells to gemcitabine in a xenograft model.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Concetta Panebianco, Federica Pisati, Annacandida Villani, Annapaola Andolfo, Marynka Ulaszewska, Edoardo Bellini, Carmelapia Ferro, Renato Lombardi, Fabrizio Orsenigo, Tiziana Pia Latiano, Beatrice Belmonte, Claudio Tripodo, Francesco Perri, Valerio Pazienza
Summary: Pancreatic cancer has a low survival rate due to late diagnosis and resistance to therapies. The authors studied the effects of a specific probiotic blend on mice with pancreatic cancer and found that it reduced chemotherapy side effects and decreased cancer-associated stromatogenesis. The results suggest that manipulating the microbiota could be a desirable strategy to improve the quality of life and increase the chance of cure for pancreatic cancer patients.
CELL DEATH DISCOVERY
(2023)
Article
Polymer Science
Kazuma Sakura, Masao Sasai, Takayuki Mino, Hiroshi Uyama
Summary: In this study, a novel treatment method using non-woven sheets containing gemcitabine (GEM) for pancreatic cancer was proposed. The sustained release of GEM from the delivery system was investigated, and significant inhibition of cell growth and tumor growth was observed, suggesting the potential usefulness of GEM-containing non-woven sheets in pancreatic cancer treatment.
Article
Oncology
Rolf D. Issels, Stefan Boeck, Uwe Pelzer, Ulrich Mansmann, Pirus Ghadjar, Lars H. Lindner, Markus Albertsmeier, Martin K. Angele, Michael Schmidt, Yujun Xu, Marcus Bahra, Johann Pratschke, Michael Schoenberg, Wolfgang E. Thasler, Christoph Salat, Oliver J. Stoetzer, Wolfram T. Knoefel, Dirk Graf, Rudiger Wessalowski, Verena Keitel-Anselmino, Alfred Koenigsrainer, Michael Bitzer, Daniel Zips, Michael Bamberg, Rainer Fietkau, Oliver Ott, Maciej Kawecki, Lucian Wyrwicz, Piotr Rutkowski, Markus Rentsch, Juliana Ababei, Peter Reichardt, Marco Rigamonti, Bernhard Weber, Sultan Abdel-Rahman, Katharina Tschoep-Lechner, Karl-Walter Jauch, Christiane J. Bruns, Helmut Oettle, Michael von Bergwelt-Baildon, Volker Heinemann, Jens Werner
Summary: In this randomized controlled trial, the addition of cisplatin to gemcitabine with regional hyperthermia did not significantly improve disease-free survival in resected pancreatic ductal adenocarcinoma, but it showed a difference in post-recurrence survival and a trend for improved overall survival.
EUROPEAN JOURNAL OF CANCER
(2023)